{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:19:58Z","timestamp":1793996398616,"version":"4.8.0"},"reference-count":94,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Rheumatoid arthritis (RA) is a systemic inflammatory disorder that characteristically affects the joints. RA has extra-articular manifestations that can impact multiple organ systems including the heart, lungs, eyes, skin, and brain. Cardiovascular involvement is a leading cause of mortality in RA. Cardiovascular manifestations of RA include accelerated atherosclerosis, heart failure, pericarditis, myocarditis, endocarditis, rheumatoid nodules, and amyloidosis. Inflammation is an important mediator of endothelial dysfunction and is a key driver of cardiovascular risk and complications in patients with RA. Prompt identification of cardiac pathologies in patients with RA is essential for appropriate management and treatment. Choosing the most appropriate treatment regimen is based on individual patient factors. In this article, we provide a comprehensive review of the epidemiology, pathophysiology, clinical manifestations, diagnosis, and medical management of cardiovascular manifestations of RA. We also discuss the relationship between anti-rheumatic medications, specifically non-steroidal anti-inflammatory drugs, corticosteroids, methotrexate, statins, tumor necrosis factor inhibitors, interleukin-6 inhibitors, Janus kinase inhibitors, and cardiovascular disease.<\/jats:p>","DOI":"10.1097\/crd.0000000000000486","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:34:51Z","timestamp":1675355691000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":41,"title":["Cardiovascular Manifestations in Rheumatoid Arthritis"],"prefix":"10.1097","volume":"32","author":[{"given":"Nirali","family":"Sanghavi","sequence":"first","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenne P.","family":"Ingrassia","sequence":"additional","affiliation":[{"name":"New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sindhuja","family":"Korem","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ash","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Westchester Medical Center\/New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wasserman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Westchester Medical Center\/New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.berh.2018.10.005","article-title":"Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis.","volume":"32","author":"van der Woude","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1186\/ar578","article-title":"Epidemiology and genetics of rheumatoid arthritis.","volume":"4","author":"Silman","year":"2002","journal-title":"Arthritis Res"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis.","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"223","DOI":"10.31138\/mjr.28.4.223","article-title":"Primary asthenic gout by Augustin-Jacob Landre-Beauvais in 1800: is this the first description of rheumatoid arthritis?","volume":"28","author":"Tsoucalas","year":"2017","journal-title":"Mediterr J Rheumatol"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jcmg.2014.12.024","article-title":"Rheumatoid arthritis: mapping the future.","volume":"8","author":"Prasad","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"e001987","DOI":"10.1136\/openhrt-2022-001987","article-title":"Risk of out-of-hospital cardiac arrest in patients with rheumatoid arthritis: a nationwide study.","volume":"9","author":"Hegazy","year":"2022","journal-title":"Open Hear"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1476-5381.2011.01367.x","article-title":"Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk.","volume":"164","author":"Varr\u00f3","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"suppl 4","key":"R9-20250619","doi-asserted-by":"crossref","first-page":"iv4","DOI":"10.1093\/rheumatology\/kel313","article-title":"The heart and cardiovascular manifestations in rheumatoid arthritis.","volume":"45","author":"Voskuyl","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2174\/138161212799504795","article-title":"Rheumatoid arthritis: cardiovascular manifestations, pathogenesis, and therapy.","volume":"18","author":"Mellana W","year":"2012","journal-title":"Curr Pharm Des"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2015.40","article-title":"Atherosclerosis in rheumatoid arthritis: is it all about inflammation?","volume":"11","author":"Skeoch","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"147354","DOI":"10.1155\/2012\/147354","article-title":"Atherosclerosis and rheumatoid arthritis: more than a simple association.","volume":"2012","author":"Cavagna","year":"2012","journal-title":"Mediators Inflamm"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jacc.2007.06.040","article-title":"Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events.","volume":"50","author":"Liuzzo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00296-020-04616-2","article-title":"The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk.","volume":"40","author":"Venetsanopoulou","year":"2020","journal-title":"Rheumatol Int"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/annrheumdis-2013-204715","article-title":"The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/art.23149","article-title":"Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.","volume":"58","author":"Farragher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/03009742.2012.677063","article-title":"Association of the methionine sulfoxide reductase A rs10903323 gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis.","volume":"41","author":"Garc\u00eda-Berm\u00fadez","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.atherosclerosis.2010.10.052","article-title":"TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis.","volume":"216","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2011","journal-title":"Atherosclerosis"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update.","volume":"76","author":"Agca","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R20-20250619","first-page":"477","article-title":"Accelerated atherosclerosis in premenopausal women with rheumatoid arthritis \u2013 a 15-year follow-up study.","volume":"21","author":"Koren Krajnc","year":"2021","journal-title":"Bosn J Basic Med Sci"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s41927-021-00213-3","article-title":"Cardiovascular disease risk calculators to reflect the subclinical atherosclerosis of coronary artery in rheumatoid arthritis: a pilot study.","volume":"5","author":"Kim","year":"2021","journal-title":"BMC Rheumatol"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1515\/cmble-2015-0020","article-title":"Relationship among IL-6, LDL cholesterol and lipid peroxidation.","volume":"20","author":"Lubrano","year":"2015","journal-title":"Cell Mol Biol Lett"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrrheum.2013.91","article-title":"Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.","volume":"9","author":"Robertson","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/annrheumdis-2011-200493","article-title":"Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.","volume":"71","author":"Charles-Schoeman","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.6061\/clinics\/2018\/e203","article-title":"Relationship between circulating VCAM-1, ICAM-1, E-selectin and MMP9 and the extent of coronary lesions.","volume":"73","author":"dos Santos","year":"2018","journal-title":"Clinics"},{"issue":"suppl 10","key":"R26-20250619","article-title":"Serum vascular cell adhesion molecule-1 (VCAM-1) levels are associated with vascular dysfunction and increased cardiovascular risk in an animal model and patients with rheumatoid arthritis.","volume":"67","author":"Davies","year":"2015","journal-title":"Rheumatology"},{"key":"R27-20250619","first-page":"296","article-title":"Statin use and mortality in rheumatoid arthritis: an incident user cohort study.","volume":"27","author":"Chhibber","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1002\/art.39114","article-title":"Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study.","volume":"67","author":"Rollefstad","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects.","volume":"22","author":"Mazziotti","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc10-1677","article-title":"Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.","volume":"34","author":"Van Raalte","year":"2011","journal-title":"Diabetes Care"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus.","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"e014661","DOI":"10.1161\/JAHA.119.014661","article-title":"Heart failure risk associated with rheumatoid arthritis-related chronic inflammation.","volume":"9","author":"Ahlers","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/ard.2006.053710","article-title":"Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis.","volume":"66","author":"Maradit-Kremers","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","article-title":"Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure.","volume":"69","author":"Mantel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"115","DOI":"10.11604\/pamj-cm.2020.4.115.25381","article-title":"Rheumatoid arthritis, a rare cause of acute myocarditis: a case report.","volume":"4","author":"Mouedder","year":"2020","journal-title":"PAMJ Clin Med"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_145_17","article-title":"Full-blown rheumatoid heart and vessels associated with rheumatoid arthritis.","volume":"19","author":"Kim","year":"2019","journal-title":"Hear Views"},{"key":"R41-20250619","first-page":"850","article-title":"Review Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatment.","volume":"29","author":"Nakamura","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/13506120802524676","article-title":"Amyloidosis is frequently undetected in patients with rheumatoid arthritis.","volume":"15","author":"Koivuniemi","year":"2008","journal-title":"Amyloid"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease.","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"R44-20250619","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R45-20250619","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R46-20250619","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2018","journal-title":"N Engl J Med"},{"key":"R47-20250619","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R48-20250619","doi-asserted-by":"crossref","first-page":"161","DOI":"10.14740\/cr570e","article-title":"Chest pain due to pericardial effusion as initial presenting feature of rheumatoid arthritis: case report and review of the literature.","volume":"8","author":"Movahedian","year":"2017","journal-title":"Cardiol Res"},{"key":"R49-20250619","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/echo.13279","article-title":"Pericardial effusion due to cholesterol pericarditis in case of rheumatoid arthritis.","volume":"33","author":"Gecmen","year":"2016","journal-title":"Echocardiogr"},{"key":"R51-20250619","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1093\/eurheartj\/ehab452","article-title":"Anti-interleukin-1 agents for pericarditis: a primer for cardiologists.","volume":"43","author":"Imazio","year":"2022","journal-title":"Eur Heart J"},{"key":"R52-20250619","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ehj.2004.02.002","article-title":"Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European Society of Cardiology.","volume":"25","author":"Maisch","year":"2004","journal-title":"Eur Heart J"},{"key":"R53-20250619","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases.","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"R54-20250619","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.revmed.2018.03.020","article-title":"[Non-infective endocarditis].","volume":"39","author":"Le Bot","year":"2018","journal-title":"La Rev M\u00e9decine Interne"},{"key":"R55-20250619","doi-asserted-by":"crossref","first-page":"S819","DOI":"10.1097\/RHU.0000000000001441","article-title":"Marantic endocarditis in a long-standing untreated rheumatoid arthritis patient.","volume":"27","author":"Duggal","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"R56-20250619","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4070\/kcj.2016.46.3.425","article-title":"Non-bacterial thrombotic endocarditis in a patient with rheumatoid arthritis.","volume":"46","author":"Choi","year":"2016","journal-title":"Korean Circ J"},{"key":"R57-20250619","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.amjmed.2006.07.023","article-title":"Noninfective endocarditis in rheumatoid arthritis.","volume":"120","author":"DeLong","year":"2007","journal-title":"Am J Med"},{"key":"R58-20250619","first-page":"511","article-title":"Nonbacterial thrombotic endocarditis.","volume":"38","author":"Campos","year":"2019","journal-title":"Rev Port Cardiol (English Ed)"},{"key":"R59-20250619","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11882-014-0491-z","article-title":"Autoimmune valvular carditis.","volume":"15","author":"Breed","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"R60-20250619","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1155\/2014\/524643","article-title":"Constrictive pericarditis and rheumatoid nodules with severe aortic incompetence.","volume":"2014","author":"Beattie","year":"2014","journal-title":"Case Rep Med"},{"key":"R61-20250619","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/20009666.2017.1340731","article-title":"Large endocardial rheumatoid nodules: a case report and review of the literature.","volume":"7","author":"Vantrease","year":"2017","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"R62-20250619","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(08)61490-7","article-title":"Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.","volume":"372","author":"Baron","year":"2008","journal-title":"Lancet"},{"key":"R63-20250619","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1503\/cmaj.1041606","article-title":"Rofecoxib (Vioxx) voluntarily withdrawn from market.","volume":"171","author":"Sibbald","year":"2004","journal-title":"CMAJ"},{"key":"R64-20250619","doi-asserted-by":"crossref","first-page":"e0261239","DOI":"10.1371\/journal.pone.0261239","article-title":"Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: a systematic review and meta-analysis.","volume":"16","author":"Cheng","year":"2021","journal-title":"PLoS One"},{"key":"R65-20250619","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis.","volume":"375","author":"Nissen","year":"2016","journal-title":"N Engl J Med"},{"key":"R66-20250619","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0002-9149(01)02265-2","article-title":"Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.","volume":"89","author":"White","year":"2002","journal-title":"Am J Cardiol"},{"key":"R67-20250619","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2012-203137","article-title":"Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study.","volume":"73","author":"Lindhardsen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R68-20250619","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis.","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"R69-20250619","doi-asserted-by":"crossref","first-page":"e87965","DOI":"10.1371\/journal.pone.0087965","article-title":"Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study.","volume":"9","author":"van Sijl","year":"2014","journal-title":"PLoS One"},{"key":"R70-20250619","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14740338.2018.1483331","article-title":"Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.","volume":"17","author":"Giollo","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"R71-20250619","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","article-title":"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis.","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology"},{"key":"R72-20250619","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R73-20250619","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events.","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"R74-20250619","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R75-20250619","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3899\/jrheum.111334","article-title":"Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis - an inception cohort study.","volume":"39","author":"Ajeganova","year":"2012","journal-title":"J Rheumatol"},{"key":"R76-20250619","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3899\/jrheum.180427","article-title":"Associations between methotrexate use and the risk of cardiovascular events in patients with elderly-onset rheumatoid arthritis.","volume":"46","author":"Widdifield","year":"2019","journal-title":"J Rheumatol"},{"key":"R77-20250619","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1136\/annrheumdis-2021-220125","article-title":"Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.","volume":"80","author":"Johnson","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R78-20250619","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.cjca.2014.08.016","article-title":"Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment.","volume":"30","author":"Yogasundaram","year":"2014","journal-title":"Can J Cardiol"},{"key":"R79-20250619","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/postgradmedj-2017-135236","article-title":"Hydroxychloroquine-induced restrictive cardiomyopathy: a case report.","volume":"94","author":"Dogar","year":"2018","journal-title":"Postgrad Med J"},{"key":"R80-20250619","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/0961203317734922","article-title":"Antimalarial-induced cardiomyopathy: a systematic review of the literature.","volume":"27","author":"Tselios","year":"2018","journal-title":"Lupus"},{"key":"R81-20250619","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10067-009-1208-x","article-title":"Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?","volume":"28","author":"Cuchacovich","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R82-20250619","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis.","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R83-20250619","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.20407","article-title":"Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.","volume":"51","author":"Gonzalez-Juanatey","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R100-20250619","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.rdc.2010.02.002","article-title":"Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment.","volume":"36","author":"Kaplan","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"R84-20250619","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"R85-20250619","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor \u03b1 inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R86-20250619","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/ard.2009.119412","article-title":"Tumour necrosis factor {alpha} blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study.","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R87-20250619","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.38920","article-title":"An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy.","volume":"67","author":"Rao","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R88-20250619","doi-asserted-by":"crossref","first-page":"e0220178","DOI":"10.1371\/journal.pone.0220178","article-title":"Cardiovascular safety of tocilizumab-a systematic review and network meta-analysis.","volume":"14","author":"Castagne\u00b4","year":"2019","journal-title":"PLoS One"},{"key":"R89-20250619","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial.","volume":"71","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R90-20250619","first-page":"696","article-title":"Protein inhibitor of activated STAT3 regulates migration, invasion, and activation of fibroblast-like synoviocytes in rheumatoid arthritis.","volume":"196","author":"Lao","year":"2022","journal-title":"J Immunol"},{"key":"R91-20250619","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1093\/eurheartj\/ehab447","article-title":"The JAK \u2013 STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms.","volume":"42","author":"Baldini","year":"2021","journal-title":"Eur Heart J"},{"key":"R92-20250619","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological modifying antirheumatic drugs: 2019 update.","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R93-20250619","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase iii and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R94-20250619","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","article-title":"Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.","volume":"37","author":"Kume","year":"2017","journal-title":"Rheumatol Int"},{"key":"R95-20250619","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis.","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R96-20250619","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis.","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R97-20250619","doi-asserted-by":"crossref","first-page":"e002236","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data.","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:04:05Z","timestamp":1750334645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000486","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,21]]}}}